TearLab Refractive Surgery Dry Eye Study
Launched by TEARLAB CORPORATION · Aug 3, 2010
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
Dry eye disease is a common and major source of disability, whether occurring as a primary disorder or as a component of other diseases and its onset may be triggered or modified by exposure to systemic drugs, contact lens wear, ocular surgery and adverse environmental and work conditions. The development of a reliable, highly sensitive and specific test for the clinical diagnosis of dry eye is a major unmet clinical need, particularly to differentiate it from common conditions such as ocular allergy which exhibit similar presenting symptoms. Tear hyper-osmolarity is central to the dry eye ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female, twenty-one years of age or older.
- • Confirmed diagnosis of refractive error receiving LASIK surgery.
- • Patient motivation and willingness to cooperate with the investigator and ability to return for all visits during the study.
- Exclusion Criteria:
- • Compromised cognitive ability that may be expected to interfere with study compliance.
- • Clinically significant eyelid deformity or eyelid movement disorder that is caused by conditions such as notch deformity, incomplete lid closure, entropion, ectropion, hordeola or chalazia.
- • Previous ocular disease leaving sequelae or requiring current topical eye therapy other than for DED, including, but not limited to: active corneal or conjunctival infection of the eye and ocular surface scarring.
- • Active ocular allergy
- • Patients requiring punctual occlusion prior to surgery
- • Patients requiring cyclosporine ophthalmic emulsion prior to surgery
- • Standard exclusion criteria for refractive surgery used by each surgeon.
- • Known hypersensitivity to any of the agents used in testing
- • Ophthalmologic drop use within 2 hours of any visit
About Tearlab Corporation
TearLab Corporation is a pioneering medical technology company dedicated to advancing the diagnosis and management of ocular surface diseases, particularly dry eye syndrome. Leveraging its innovative TearLab Osmolarity System, the company focuses on developing precise, point-of-care diagnostic solutions that enhance clinical decision-making and improve patient outcomes. With a commitment to research and development, TearLab Corporation collaborates with healthcare professionals to explore new therapeutic avenues and ensure the highest standards of patient care in ophthalmology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fairfield, Connecticut, United States
Westchester, Illinois, United States
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
King Of Prussia, Pennsylvania, United States
San Antonio, Texas, United States
Salt Lake City, Utah, United States
Reston, Virginia, United States
Patients applied
Trial Officials
James Owen, OD
Study Director
TLC The Laser Eye Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials